Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with endometrial carcinoma (a type of uterine cancer) — this applies to certain parts of the trial
- People who have been diagnosed with ovarian cancer — this applies to all parts of the trial
Who may not be able to join:
- People who have cancer that has spread to the brain or spinal cord in a way that is not controlled
- People who have a history of cancer spreading to the membranes surrounding the brain and spinal cord
- People who currently have an active, uncontrolled infection caused by bacteria, a virus, fungus, or parasites
- People who have a known condition affecting the cornea (the clear front surface of the eye) or who have had a cornea transplant
- People who still have significant side effects or health problems left over from previous cancer treatments
- People who have serious heart or blood vessel disease
- People whose heart's electrical activity shows a specific abnormality (a prolonged QTcF interval of 470 milliseconds or more) on a heart tracing test (confirm with trial site)
- People who have a history of lung inflammation or scarring of the lung tissue (pneumonitis or interstitial lung disease)
- People who are pregnant, currently breastfeeding, or who plan to breastfeed during the study or within 30 days of receiving the last dose of the study treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Margaret C Dugan, MD, Whitehawk Therapeutics
Phone: 888-392-9025
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine Maximum Tolerated Dose (MTD); Determine Maximum Administered Dose (MAD); Determine Recommended Dose For Expansion (RDE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.